Evaluation of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) Functional Polymorphisms in Psoriasis Susceptibility in Egypt

Abeer ALrefai, Ashraf Dawood, Wafaa Shehata, Mohammed Elhelbawy, Nesreen Elhelbawy

Background: Psoriasis is a complex autoimmune multifactorial disease induced by interaction of environmental and genetic factors. This research aimed to clarify the association of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) polymorphisms with susceptibility to psoriasis.

Methods: This case–control study involved 150 patients diagnosed with psoriasis and 100 age- and gender-matched apparently healthy individuals. NLRP3 (rs10754558) polymorphism was done by real time PCR and PTPN22 1858C/T (rs2476601) genotype was identified by tetra-primer amplification refractory mutation system-polymerase chain reaction (PCR) method.

Results: The genotypes distribution of NLRP3 (rs10754558) were significantly associated with psoriasis (p<0.0001). Whereas for PTPN22 (1858C/T) (rs2476601), no significance was found (p=0.09). NLRP3 (rs10754558) GC genotype revealed a significant association with psoriasis (p<0.0001), mainly among male (p=0.004) patients with mild psoriasis (p=0.001) and affected extremities (p=0.0001).

Conclusion: We can conclude that the NLRP3 (rs10754558) GC genotype may play a role in psoriasis susceptibility among male Egyptian populations with affected extremities. Future studies must evaluate its role in the prevention or the treatment of psoriasis.

Keywords: psoriasis, NLRP3 (rs10754558), PTPN22 (1858C/T) (rs2476601), real time PCR

Introduction

Psoriasis is a chronic multisystem autoimmune disease. It affects 1–3% worldwide populations varying among different ethnic populations and geographical regions. Although the etiopathogenesis of psoriasis is not fully understood, it is considered as a disease with multi-factorial etiology including different genetic (either immune-specific or skin-specific genes) and non-genetic factors, such as immunological (The imbalance among CD4+ T-cell subsets contributes to hyperkeratosis and parakeratosis) and environmental risk factors (UV radiation exposure, some medications, smoking, alcohol intake, infections, and stress). Nowadays the interaction between all these factors is the main factor in the pathogenesis of psoriasis. NLRP3 (NOD-like receptor family, pyrin domain-containing subfamily) is activated in skin inflammatory diseases, but its attribution in psoriasis is still questioned. The role of NLRP3 inflammasome in psoriasis has received widespread attention and recognition. Variable studies have indicated that activation of NLRP3...
inflammasesome may contribute to psoriasis inflammatory response.4,5 The relationship between NLPR3 and psoriasis from the perspective of genetic polymorphisms demonstrated that two single nucleotide polymorphisms (SNPs), rs3806265 and rs10754557, in NLPR3 were significantly related to Psoriasis Vulgaris (PsV).5 Protein tyrosine phosphatase non-receptor 22 (PTPN22) gene, presented on chromosomes 1p13.3 to p13.1, encodes a lymphoid-specific phosphatase (Lyp). It was found that PTPN22 interacts with and dephosphorylates NLPR3 upon proinflammatory insults, permitting robust NLPR3 activation and interleukin (IL-1β) secretion.6 It targets different signaling intermediates involved in T-cell receptor signaling and may work at many levels in the signaling cascade.7 Single nucleotide polymorphism (SNP) in PTPN22 gene 1858C/T (rs2476601) (exon 14) has been associated with the number of autoimmune diseases and considered as a risk factor due to induction of auto antibodies production.8 A limited number of studies have evaluated the association of NLPR3 genetic locus (rs10754558) with psoriasis. To explore this important issue, we investigated the association of NLPR3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) polymorphisms with susceptibility to psoriasis.

Materials and Methods

Subjects

This case-control study involved 150 patients diagnosed with psoriasis in the dermatology clinic of Menoufia University Hospital and 100 age- and gender-matched apparently healthy people served as the control group. They were examined and diagnosed by dermatologists depending on the clinical findings, skin changes, and the location of the condition on the body and skin biopsy (when indicated). The demographic data and Psoriasis Area and Severity Index (PASI) score were recorded. (PASI score was determined following the work by Fredriksson and Pettersson; mild psoriasis: PASI is <10, moderate psoriasis: PASI is 10–20, severe psoriasis: PASI is >20).9 All patients diagnosed with plaque psoriasis for at least 1 year were included in the study. Exclusion criteria were coexisting or family history of any other dermatological disorders (controls also), hypothyroidism, autoimmune diseases and renal/liver failure. This study was approved by the Ethical Committee, Faculty of medicine Menoufia University and performed in accordance with the Declaration of Helsinki. All participants were informed and signed consent forms before being included. NLPR3 (rs10754558) polymorphism was done by real time PCR and PTPN22 1858C/T (rs2476601) genotype was identified by tetra-primer amplification refractory mutation system-polymerase chain reaction (PCR) method.

Methods

Five milliliters of venous blood were collected in an EDTA tube for DNA extraction and genotyping of NLPR3 (rs10754558) and PTPN22 1858C/T (rs2476601).

DNA Extraction and Genotyping

Genomic DNA was extracted and purified from whole blood utilizing QIAamp DNA Mini Kit (QIAGEN, USA, 2012)10 according to the manufacturer’s protocol. Purified DNA was quantified using the Nano-Drop spectrophotometer and stored at −20 until analysis. NLPR3 (rs10754558) G>C SNP was identified by TaqMan 5’ bi-allelic discrimination assay using primers and probes from Applied Biosystems (Foster City, CA, USA) and utilizing the 7500 Real-time PCR system. The provided fluorescent labeled TaqMan probes were sequenced as: *GACAATGACAGCATCGGGTTTGT [C/G]TCATCACACCGCTCTAGTTAGGA (VIC dye for allele C and FAM dye for allele G). To detect the selected SNPs, real-time PCR was set with a reaction volume of 25 µL using 12.5 µL of TaqMan Genotyping Master Mix, 1.25 µL of 20× SNP assay mixture of probes and primers, 6.25 µL of nuclease-free water, and 5 µL of the extracted DNA. The reaction was completed in 96-well plates and proceeded as described: 94°C for 4 minutes (pre-PCR read), then 50 cycles of 30 seconds for denaturation at 94°C, 25 seconds for primer annealing at 50°C, 40 seconds for extension at 72°C, and finally 3 minutes at 72°C for post-PCR.11

PTPN22 (rs2476601) 1858C/T genotypes were identified by tetra-primer amplification refractory mutation system. The genomic DNA was amplified by using two external primers (forward outer primer: 5’-CTCACACATCG CTTCCAAAAGTG-3’ and reverse outer primer: 5’-CAACTTTACTGATAATGTTC GC TTCAAAGGA-3’) and two internal primers (forward inner primer: 5’-CAACACACAAATATG ATTCAGGTGTAC-3’, reverse inner primer: 5’-ATCCCCCCCTGACTTCTGGAAT-3’). Product sizes were 213 and 151 bp (base pairs) for the C- and T-alleles, respectively, but the product size of the internal...
control was 314 bp. The PCR cycling conditions were as shown: 5 minutes at 95°C followed by 30 cycles (30 seconds at 95°C, 30 seconds at 64°C and 30 seconds at 72°C) and 10 minutes at 72°C. The all PCR products were electrophoresed on 2% agarose gels and photographed.12

Statistical Analysis

Data were statistically analyzed by SPSS version 16 (SPSS Chicago., Inc.). Mann–Whitney test was used for non-parametric variables. Chi-Squared and Fisher’s exact tests were used for used qualitative variables. A p-value<0.05 was considered significant.

Results

This is a case-control study involving 150 patients whose mean ages were 42.7±16.1 years; 105 (70%) were male and 45 (30%) were female, 30 (20%) of them have a family history of psoriasis, 24 (16%) were diabetics, nine (6%) were hypertensive, and 12 (8%) were combined diabetics and hypertensive. One hundred apparently healthy individuals were selected as a control group whose mean ages were 39.6±14.4 years; 60 (60%) were male and 40 (40%) were female. Both patients and control groups were matched for age (p=0.13) and gender (p=0.1). Thirty-nine (26%) of the patients were smokers versus 40 (40%) among the control group (p=0.02) (Table 1).

A total of 81 patients (54%) had mild, 39 patients (26%) had moderate, and 30 patients (20%) presented severe psoriasis. Seventy-two (48%) of the patients suffered from early onset psoriasis and 78 (52%) of them had late onset psoriasis. Twenty-three (22%) of the psoriatic patients had a progressive course versus 12 (8%) and 105 (70%), who had stationary and regressive courses, respectively. Scalp, joint, nail, palm, and sole involvement were detected in 69 (46%), 33 (22%), 36 (24%), and 57 (38%) patients, respectively, and their median PSAI score was 8.2 (Table 2).

Younger (p<0.0001), non-smoker (p<0.0001), with age of onset <40 years (p=0.0002) revealed significant associations with severe psoriasis. On the other hand male gender was more among patients with mild and moderate psoriasis (p=0.018). As expected, severe psoriasis was characterized by early-onset (p=0.03), progressive course (p=0.0001), itching (p=0.0003), involvement of scalp (p=0.0002), involvement of both axilla and extremities (p=0.0001), with no associated DM or HTN (p=0.0001) (Table 3).

The genotype and allele frequencies of rs10754558 SNP of NLRP3 in the studied groups are presented in Table 4. For the control group the genotype distribution was 40 (40%) GG, 20 (20%) GC, and 40 (40%) CC; while for the patients GG was 36 (24%), GC was 81 (54%), and CC was 33 (22%). The GC genotype revealed a significant association with psoriasis (p<0.0001), while the allele showed a non-significant association with psoriasis (p=0.9). CC genotype revealed a significant decrease among patients compared to controls (p<0.0001).

The GC genotype of rs10754558 SNP was significantly associated with mild psoriasis (p=0.001) and affected extremities (p=0.0001) mainly among male patients (p=0.004) with a progressive course (p=0.03) (Table 5).

On the other hand, PTPN22 1858C/T (rs2476601) genotype; CC 102 (68%), CT 47 (31.3%), and TT 1 (0.7%) in patients versus CC 80 (80%), CT 20 (20%), and TT 0 (0%) in the control group (p=0.09) revealed a non-significant association with psoriasis, while the allele frequency (p<0.05) showed critical level significance (Table 6).
Table 2 Description of Psoriasis Among Patients

| Variables                  | Patients (N=150) |
|---------------------------|------------------|
| Onset                      |                  |
| Early                      | No (%): 72 (48)  |
| Late                       | No (%): 78 (52)  |
| Course Stationary          |                  |
| Progressive                | No (%): 23 (22)  |
| Regressive                 | No (%): 105 (70) |
| Stationary                 | No (%): 12 (8)   |
| Duration (years)           | Median: 9 (0.5–12) |
| Site                       |                  |
| Extremities                | No (%): 75 (50)  |
| Axial                      | No (%): 15 (10)  |
| Axial & Extremities        | No (%): 60 (40)  |
| Scalp                      |                  |
| Yes                        | No (%): 69 (46)  |
| No                         | No (%): 81 (54)  |
| Nail                       |                  |
| Yes                        | No (%): 36 (24)  |
| No                         | No (%): 114 (76) |
| Joint                      |                  |
| Yes                        | No (%): 33 (22)  |
| No                         | No (%): 117 (78) |
| Palm/Sole                  |                  |
| Yes                        | No (%): 57 (38)  |
| No                         | No (%): 93 (62)  |
| Itching                    |                  |
| Yes                        | No (%): 45 (30)  |
| No                         | No (%): 105 (70) |
| Koebnerization             |                  |
| Yes                        | No (%): 21 (14)  |
| No                         | No (%): 129 (86) |
| PASI Score                 | Median: 8.2 (0.3–24.4) |
| Severity                   |                  |
| Mild (PASI<10)             | No (%): 81 (54)  |
| Moderate (PASI=10–20)      | No (%): 39 (26)  |
| Severe (PASI>20)           | No (%): 30 (20)  |

Table 3 Correlation Between Psoriasis Severity and Different Variables

| Variables                  | Patients (N=150) |
|---------------------------|------------------|
| Age (years)               |                  |
| <50                       | No (%): 54 (66.7) |
| >50                       | No (%): 27 (33.3) |
| Gender                    |                  |
| Male                      | No (%): 63 (77.8) |
| Female                    | No (%): 18 (22.2) |
| Smoking                   |                  |
| Yes                       | No (%): 15 (18.5) |
| No                        | No (%): 66 (81.5) |
| Age of onset              |                  |
| <40                       | No (%): 42 (51.9) |
| >40                       | No (%): 39 (48.1) |
| Onset                     |                  |
| Early                     | No (%): 42 (51.9) |
| Late                      | No (%): 39 (48.2) |
| Course                    |                  |
| Stationary                | No (%): 27 (33.3) |
| Progressive               | No (%): 48 (59.2) |
| Regressive                | No (%): 6 (7.4)  |
| Family history            |                  |
| Yes                       | No (%): 15 (18.5) |
| No                        | No (%): 66 (81.5) |
| Without DM or HTN         |                  |
| With DM                   | No (%): 12 (14.8) |
| With HTN                  | No (%): 9 (11.1)  |
| Combined                  | No (%): 0 (0)    |
| Site                      |                  |
| Extremities               | No (%): 51 (63)  |
| Axilla                    | No (%): 15 (18.5) |
| Combined                  | No (%): 15 (18.5) |
| Scalp                      |                  |
| Yes                       | No (%): 30 (37)  |
| No                        | No (%): 51 (63)  |

Discussion

Psoriasis is an inflammatory immune-mediated disease with a complex genetic basis. Psoriasis can be correlated to multiple genes associated with linkage disequilibrium in

(Continued)
Table 3 (Continued).

| Variables | No (% | Moderate Psoriasis (N=39) | Severe Psoriasis (N=30) |
|-----------|-------|---------------------------|-------------------------|
| Itching   |       |                           |                         |
| Yes       | 18 (22.2) | 9 (23.1)                 | 18 (60)                 |
| No        | 63 (77.8) | 30 (76.9)               | 12 (40)                 |

Notes: *Statistically significant at p≤0.05. Mild (PASI<10), Moderate (PASI=10–20), Severe (PASI>20). PASI score (Median (Range))=8.2 (0.3–24.4).

The Application of Clinical Genetics downloaded from https://www.dovepress.com/ by 207.241.232.187 on 04-Aug-2021
For personal use only.

Table 4 Genetic Distribution of NLRP3 (rs10754558) Among Studied Groups

| Genotype | Groups | p-value |
|----------|--------|---------|
|          | Patients (N=150) | Control (N=100) |
|          | N (%) | N (%)  |          |
| GG       | 36 (24) | 40 (40) | <0.0001* |
| GC       | 81 (54) | 20 (20) |          |
| CC       | 33 (22) | 40 (40) |          |
| Allele   |         | 0.9     |          |
| G        | 153 (51) | 100 (50) |          |
| C        | 147 (49) | 100 (50) |          |

Notes: *Statistically significant at p≤0.05.

NLRP3 are candidate genes that could induce susceptibility to auto-inflammatory conditions.20

Our study evaluated the relationship of NLRP3 rs10754558 and (PTPN22) 1858C/T (rs2476601) polymorphisms with susceptibility to psoriasis.

In the current study, the GC genotype of NLRP3 (rs10754558) was significantly associated with risk of psoriasis mainly among psoriatic male with mild psoriasis and affected extremities, thus underlining the importance of NLRP3 signaling in the development of psoriasis.

Conflicting results for the association of NLRP3 (rs10754558) and development of psoriasis have previously been reported.

The genotypes of NLRP3rs10754558 influenced the extent of systemic inflammation, suggesting that the SNP at the NLRP3 rs10754558 locus may modulate inflammasome activation and contribute to adverse inflammatory outcomes.21 On the other hand, Irrera et al22 confirmed the partial role of NLRP3 in the development of psoriasis. They reported that BAY 11–7082, an antagonist of NF-κB, can alleviate psoriasis-like dermatitis by inhibiting the NLRP3 inflammasome and the NF-κB pathway. Furthermore, Lee and Bae18 reported a significant association between the NLRP3 rs10754558 C/G polymorphism and both inflammatory and autoimmune diseases in Latin American individuals, but not in Europeans and Asians. However, this meta-analysis did not identify an association between it and gout and celiac disease, that could be explained by a disease-specific effect or unknown factors.18

Numerous researches have cleared the association of the gene polymorphisms of NLRP3 rs10754558 with susceptibility to diseases23 such as aspirin-induced asthma,24 abdominal aortic aneurysms, and common inflammatory disorders.25 Also, Su et al4 proved that NLRP3 is significantly upregulated in psoriatic tissues and its expression is associated with upregulation of caspase-1 leading to secretion of IL-1β and IL-18, which are involved in inflammation and immune response. The altered expression of these proteins indicates their potential role in psoriasis. Thus, NLRP3 inhibition could interrupt the pathological mechanisms underlying the triggering and the maintenance of psoriasis lesions.22

The NLRP3 rs10754558 C/G polymorphism may affect its mRNA stability and expression. The rs10754558 C allele decreases the stability of NLRP3 mRNA in comparison with the rs10754558 G allele. Moreover, the allele-specific construct containing the
G allele of the rs10754558 shows a 1.3-fold higher activity than that containing the C allele.\textsuperscript{24,25} Notably, the NLRP3 rs10754558-G allele was additionally linked to high IL-18 levels, suggesting that this SNP may modulate inflammasome induction and contribute to unwanted inflammatory outcomes.\textsuperscript{21}

Many autoimmune diseases can nowadays be treated with IL-1β and IL-18 antagonists or their receptors.\textsuperscript{26} However, it was found that targeting NLRP3 might present certain advantages over the use of IL-1β biologic inhibitors.\textsuperscript{27}

It has been shown that the TNF-α-mediated activation of NLRP3 inflammasomes in psoriatic patients can contribute to systemic inflammation. Anti-TNF therapy normalized the inflammasome function, suggesting a mechanism for the cardiovascular risk-reducing effect.\textsuperscript{28}

On the other hand, Loft et al\textsuperscript{29} reported that variants in genes involved in pattern recognition (TLRs and NOD-like receptors) pathways could not predict a response in patients treated with either anti-TNF or ustekinumab.

Several studies suggested that activation of NLRP3 is regulated by protein tyrosine phosphatase non-receptor 22 (PTPN22). Spalinger et al\textsuperscript{30} explained how loss of PTPN22 and subsequent enhanced NLRP3 phosphorylation mediate depressed NLRP3 inflammasome activation and IL1B secretion. The presence of a variant in the gene

| Risk Groups                  | Genotyping | p-value |
|------------------------------|------------|---------|
|                              | GG (N (%)) | GC (N (%)) | CC (N (%)) |
| Psoriatic males              | 21 (58.3)  | 66 (81.5)  | 18 (54.5)  |
| Psoriatic females            | 15 (41.7)  | 15 (18.5)  | 15 (45.5)  |
| Smokers                      | 9 (25)     | 24 (29.6)  | 6 (18.2)   |
| Non-smokers                  | 27 (75)    | 57 (70.4)  | 27 (81.8)  |
| Early onset                  | 21 (58.3)  | 36 (44.4)  | 15 (45.5)  |
| Late onset                   | 15 (41.7)  | 45 (55.6)  | 18 (54.5)  |
| Course                       |            |          | 0.03*      |
| Stationary                   | 9 (25)     | 21 (25.9)  | 3 (9.1)    |
| Progressive                  | 27 (75)    | 54 (66.7)  | 24 (72.7)  |
| Regressive                   | 0 (0)      | 6 (7.4)    | 6 (18.2)   |
| With DM or HTN               | 27 (75)    | 57 (70.4)  | 21 (63.6)  |
| Without DM or HTN            | 9 (25)     | 24 (29.6)  | 12 (36.4)  |
| Presence of family history   | 3 (8.3)    | 21 (25.9)  | 6 (18.2)   |
| No family history            | 33 (91.7)  | 60 (74.1)  | 27 (81.8)  |
| Site                         |            |          | 0.0001*    |
| Extremities                  | 12 (33.3)  | 54 (66.7)  | 9 (27.3)   |
| Combined                     | 24 (66.7)  | 15 (18.5)  | 21 (63.6)  |
| Axillary                     | 0 (0)      | 12 (14.8)  | 3 (9.1)    |
| Severity                     |            |          | 0.001*     |
| Mild (PASI<10)               | 15 (41.7)  | 51 (63)    | 15 (45.5)  |
| Moderate (PASI=10–20)        | 9 (25)     | 24 (29.6)  | 6 (18.2)   |
| Severe (PASI>20)             | 12 (33.3)  | 6 (7.4)    | 12 (36.4)  |

Notes: *Statistically significant at p≤0.05.
coding for PTPN22 promotes inflammasome activity. This variant is associated with increased risk to develop many chronic inflammatory disorders.

On the other hand, our study revealed a non-significant association of PTPN22 1858C/T (rs2476601) genotype with risk of psoriasis.

The PTPN22 gene encodes LYP, a functional protein tyrosine phosphatase, a regulator of the negative regulatory kinase in T-cells, inducing suppression of T-cells and, therefore, maybe the mechanism by which this association contributes to the genetic susceptibility of autoimmune disorders.31

Inconsistent with our result, Bin Huraib et al12 proved a weak association between the heterozygous CT genotype of the PTPN22 (1858C/T) gene functional variant and risk of psoriasis. Interestingly, the homozygous TT genotype was not detected at all in either patients or the controls in this study from Saudi Arabia.12

Loft et al32 documented a non-significant association of PTPN22 (rs2476601) as a risk factor of psoriatic arthritis (PsA). Also, Stuart et al33 could not confirm any association of this subphenotype with Psoriasis. In addition, Bowes et al34 reported a genome-wide significant association of PTPN22 (rs2476601) to PsA susceptibility, whereas no evidence for association to psoriasis. Further analysis showed an insignificant association with PTPN22 C1858T manifest in skin, the gastrointestinal tract or immune privileged sites. Revealing that the association of PTPN22 polymorphism with autoimmune diseases may depend on the localization of the affected tissue, demonstrating a role of targeted organ variation in the disease manifestations.35 Also, Chen and Chang36 showed a non-significant positive association between psoriasis and PTPN22 1858 T-allele, and the association appeared more strong among subjects with psoriatic arthritis. Recently, Al-Awadhi et al37 stated that the frequency of homozygous genotype (TT) was significantly higher in PsA patients compared to controls (p<0.0001) in Kuwaiti Arabs. However, previous studies from various geographical regions/ethnic populations on PTPN22 (+1858C/T) polymorphism and psoriasis have reported inconsistent conclusions, indicating that this association might be disease- and population-specific.

Conclusions

Our study indicated that the NLRP3 (rs10754558) GC genotype may play a role in psoriasis susceptibility among male Egyptian populations with affected extremities. Future studies must evaluate its role in the prevention or the treatment of psoriasis.

Ethical Statement

This study was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all the participants, approved by the Ethical Committee of Medical Research, Faculty of Medicine, Menoufia University.

Acknowledgments

We appreciate all patients and controls who contributed in this study.

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850. doi:10.1016/j.jaad.2008.02.039
2. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. doi:10.1016/j.jaut.2015.07.008
3. Boehncke WH, Schöhn MP. Psoriasis. Lancet. 2015;386:983–994. doi:10.1016/S0140-6736(14)61909-7
4. Su F, Xia Y, Huang M, Zhang L, Chen L. Expression of NLPR3 in psoriasis is associated with enhancement of Interleukin-1beta and Caspase-1. Med Sci Monit. 2018;24:7909–7913. doi:10.12659/MSM.911347

Table 6 Genetic Distribution of PTPN22 1858C/T (rs2476601) Genotypes Among Studied Groups

| Genotype | Patients (N=150) | Control (N=100) | p-value |
|----------|-----------------|----------------|---------|
|          | N (%)           | N (%)          |         |
| CC       | 102 (68)        | 80 (80)        | 0.09    |
| CT       | 47 (31.3)       | 20 (20)        |         |
| TT       | 1 (0.7)         | 0 (0)          |         |
| Allele   |                 |                | <0.05*  |
| C        | 251 (83.66)     | 180 (90)       |         |
| T        | 49 (16.33)      | 20 (10)        |         |

Notes: *Statistically significant at p≤0.05.
5. Yu P, Hao S, Zheng H, Zhao X. Association of NLRP1 and NLRP3 polymorphisms with psoriasis vulgaris risk in the Chinesean population. *Biomed Res Int.* 2018;4:714–836.

6. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. *Blood.* 1999;93:2013–2024. doi:10.1182/blood.V93.6.2013.406k25. 2013 2024

7. Bianco B, Verreschi IT, Oliveira KC, et al. PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome. *Scand J Immunol.* 2010;72:256–259. doi:10.1111/j.1365-3083.2010.02438.x

8. Padhan V, Borse V, Ghosh K. PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythe-matosus disease susceptibility. *J Postgrad Med.* 2010;56:239–242. doi:10.4103/0022-3859.68651

9. Fredriksson T, Pettersson U. Severe psoriasis- oral therapy with a new retinoid. *Dermatology.* 1978;157:238–244. doi:10.1159/000020839

10. ipsofen® RT Kit Handbook. QIAGEN GmbH; 2015. Available from: http://rcostoya.com/uploads/galerias/con812/hb-1356-003-107504-151021522-r3-ipsofen-rt-kit-ce-0315-row.pdf.

11. Afonina I, Zivarts M, Kutyanin I, Lukhtanov E, Gampier H, Meyer RB. Efficient priming of PCR with short oligonucleotides conjugated to a minor groove binder. *Nucleic Acids Res.* 1997;25(13):2657–2660. doi:10.1093/nar/25.13.2657

12. Bin Hurabi G, Al Harthi F, Arfin M, Rizvi S, Al-Asmari A. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) R620W functional polymorphism in psoriasis. *Clin Med Insights Arthritis Musculoskelet Disord.* 2017;11:1–6.

13. Lowes MA, Suárez-Fariñas M, Kneuger JG. Immunology of psoriasis. *Ann Rev Immunol.* 2014;32:227–255. doi:10.1146/annurev-immunol-032713-120225

14. Chandy S, Song J. Association of NLRP1 and NLRP3 gene polymorphism with psoriasis. *Our Dermatol Online.* 2020;11(3):275–283. doi:10.7241/ourd.20203.13

15. Bitto A, Altavilla D, Pizzino G, et al. Inhibition of inflammasome pathway modulates severity of psoriasis. *J Postgrad Med.* 2016;62(4):202–207. doi:10.4103/0378-6323.185084

16. Chiazza F, Couturier-Maillard A, Benetti E, et al. Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. *Mol Med.* 2015;21:1025–1037. doi:10.2119/molmed.2015.00104

17. Villani A, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. *Nat Genet.* 2009;41(1):71–76. doi:10.1038/ng.285

18. Lee YH, Bae SC. Association between functional NLRP3 polymorphisms and susceptibility to autoimmune and inflammatory diseases: a meta-analysis. *Lupus.* 2016;25:1558–1566.

19. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. *Nature.* 2001;411(6837):603–606. doi:10.1038/35079114

20. Roberts RL, Van Rij AM, Phillips LV, et al. Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms. *Atherosclerosis.* 2011;218(1):123–126. doi:10.1016/j.atherosclerosis.2011.04.043

21. Ravimohan S, Nfangaya K, Tamulha N, Tiemens TT, Weissma D, Bisson GP. Common variation in NLRP3s associated with early death and elevated inflammasome biomarkers among advanced HIV/TB co-infected patients in Botswana. *Open Forum Infect Dis.* 2018;5:75. doi:10.1093/ofid/ofy075

22. Irrera N, Vaccaro M, Bitto A, et al. BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. *Clin Sci.* 2017;131:487–498. doi:10.1042/CS20160645

23. Paramel GV, Sirsój A, Fransén K. Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease. *Mediators Inflamm.* 2015;2015:846782.

24. Hitomi Y, Ebisawa M, Tomikawa M, et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. *J Allergy Clin Immunol.* 2009;124(4):779–785. doi:10.1016/j.jaci.2009.07.044

25. Verma D, Lerm M, Julinder RB, Eriksson P, Söderkvist P, Särndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation relation to common inflammatory diseases? *Arthritis Rheum.* 2008,58(3):888–894. doi:10.1002/art.23286

26. Perera AP, Kunde D, Eri R. NLRP3 inhibitors as potential therapeutic agents for treatment of inflammatory bowel disease. *Curr Pharm Des.* 2017;23:2321–2327. doi:10.2174/1381612823666170201162414

27. Liu L, Dong Y, Ye M, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. *J Crohns Colitis.* 2017;11:737–750. doi:10.1093/ecto-jcc/jiw219

28. Verma D, Fekri SZ, Sigurdardottir G, Eding CB, Sandin C, Enerbäck C. Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation. *J Invest Dermatol.* 2020;141:586–595.e5. doi:10.1016/j.jid.2020.07.012

29. Loft ND, Skov L, Iversen L, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. *Pharmacogenomics.* 2018;19:494–500. doi:10.1080/10849501.2017.131

30. Spalinger M, Lang S, Gottlier C, et al. PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. *Autoagy.* 2017;13:1590–1601. doi:10.1080/15548627.2017.1341453

31. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. *Nat Genet.* 2005;37(12):1317–1319. doi:10.1038/ng1673

32. Loft ND, Skov L, Iversen L, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. *PLoS One.* 2018;13:e0192010. doi:10.1371/journal.pone.0192010

33. Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. *Am J Hum Genet.* 2015;97(6):816. doi:10.1016/j.ajhg.2015.10.019

34. Bowes J, Loehr S, Budu-Aggrey A, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. *Ann Rheum Dis.* 2015;74(10):1882–1885. doi:10.1136/annrheumdis-2014-207187 PMID: 25923216; PubMed Central PMCID: PMCPMC4602265.

35. Zheng J, Ibrahim S, Petersen F, Yu X. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. *Genes Immun.* 2012;13:641–652. doi:10.1038/gi.2012.46

36. Chen YF, Chang JS. PTPN22 C1858T and the risk of psoriasis: a meta-analysis. *Mol Biol Rep.* 2012;39(8):7861–7870. doi:10.1007/s11033-012-1630-z

37. Al-Awadhi A, Haider M, Sukumaran J, Mohammed A, Hasan E, Bartella Y. Role of Protein Tyrosine Phosphatase (PTPN22) gene [C1858T] functional variant in genetic susceptibility of psoriatic arthritis in Kuwaiti Arabs. *Open Rheumatol J.* 2020;14:15–21. doi:10.2174/1874312920140010015
The Application of Clinical Genetics

Publish your work in this journal

The Application of Clinical Genetics is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings in the field of human genetics. Specific topics include: Population genetics; Functional genetics; Natural history of genetic disease; Management of genetic disease; Mechanisms of genetic disease; Counselling and ethical issues; Animal models; Pharmacogenetics; Prenatal diagnosis; Dysmorphology. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/the-application-of-clinical-genetics-journal